New therapeutic paradigm for patients with cirrhosis

Area of Science:

• Hepatology and Gastroenterology
• Internal Medicine

Background:

• Cirrhosis is a significant global health issue with high mortality rates, particularly in decompensated stages.
• Historically viewed as a terminal condition, recent evidence highlights a wide mortality spectrum from early to decompensated cirrhosis.
• Liver transplantation remains the sole definitive treatment for advanced cirrhosis, underscoring the need for preventative strategies.

Purpose of the Study:

• To advocate for a proactive management approach in compensated cirrhosis.
• To propose a strategy focused on preventing complications rather than treating them reactively.
• To introduce a cost-effective therapeutic regimen using existing medications to maintain patients in an asymptomatic phase.

Main Methods:

• Review of current evidence on cirrhosis progression and management.
• Proposal of a combination therapy including propranolol, simvastatin, norfloxacin, and warfarin.
• Estimation of the annual cost-effectiveness of the proposed drug combination.

Main Results:

• The proposed management strategy aims to prevent the transition to decompensated cirrhosis.
• The combination therapy is projected to cost approximately £128/$196 per patient annually.
• This approach emphasizes maintaining patient quality of life with minimal therapeutic impairment.

Conclusions:

• Cirrhosis should be considered a potentially treatable disease in the 21st century.
• A paradigm shift towards preventative management in compensated cirrhosis is warranted.
• Randomized controlled trials are necessary to validate the proposed treatment strategy and its impact on patient outcomes.